Core Insights - WuXi Biologics (02269) reported a 16.1% year-on-year revenue growth for the first half of 2025, reaching RMB 9.95 billion, with a 20.2% increase in revenue from continuing operations [1] - The company's overall profitability improved significantly, with EBITDA rising by 50.5% to RMB 4.22 billion and net profit increasing by 54.8% to RMB 2.76 billion [1] - Adjusted net profit grew by 11.6% to RMB 2.84 billion, with an adjusted net profit margin of 28.5% [1] - The strong performance led the company to raise its full-year revenue guidance for 2025 to a range of 14%-16% [1] - The total value of unfulfilled orders exceeded USD 20.34 billion, with unfulfilled orders over the next three years increasing to USD 4.21 billion, indicating a substantial growth in revenue expectations [1]
药明生物上半年收益近百亿元，未完成订单总额超200亿美元